EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR T-cell therapy to treat multiple myeloma: current state and future directions

Siddhartha Thammineni Reddy, Hitomi Hosoya, Lekha Mikkilineni

Cancer and Metastasis Reviews · 2025

DOI: 10.1007/s10555-024-10219-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, 2025. Verfasst von Siddhartha Thammineni Reddy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, 870 Welch Road, Palo Alto, CA, 94304, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in treating relapsed or refractory multiple myeloma (MM) in both early- and late-line settings. MM, a plasma cell malignancy, traditionally requires ongoing complex drug regimens, posing significant burdens on patients. In contrast, CAR T-cell therapy offers a one-time treatment option without the need for continuous maintenance therapy. CAR T-cell therapy leverages engineered T-cells to target specific antigens on tumor cells, leading to their elimination. Current approved therapies target B-cell maturation antigen (BCMA); new targets are under investigation, such as G-protein-coupled receptor class C group 5 member D (GPRC5D). Despite its efficacy, CAR T-cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS), necessitating careful management. The review will provide an overview of the design and manufacturing of CAR T-cells and current FDA indications, as well as challenges and future directions of CAR-T therapy for MM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsT-Lymphocytes

Stichwörter der Autor:innen

CAR TCell therapy, Indication of CAR TCellsCells, Resistance mechanisms of CAR TCells, Toxicities of CAR T

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, 870 Welch Road, Palo Alto, CA, 94304, USA.
  • Hackensack University Medical Center, NJ, USA.
  • Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, 870 Welch Road, Palo Alto, CA, 94304, USA. lekham@stanford.edu.

Zitieren

APA

Reddy, S. T., Hosoya, H., & Mikkilineni, L. (2025). CAR T-cell therapy to treat multiple myeloma: current state and future directions. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-024-10219-1

Vancouver

Reddy ST, Hosoya H, Mikkilineni L. CAR T-cell therapy to treat multiple myeloma: current state and future directions. Cancer and Metastasis Reviews. 2025. doi:10.1007/s10555-024-10219-1

BibTeX
@article{Reddy2025,
  author = {Reddy, Siddhartha Thammineni and Hosoya, Hitomi and Mikkilineni, Lekha},
  title = {CAR T-cell therapy to treat multiple myeloma: current state and future directions},
  journal = {Cancer and Metastasis Reviews},
  year = {2025},
  doi = {10.1007/s10555-024-10219-1}
}
Kostenlos starten →